Tiziana Life Sciences Ltd

Snapshot

Tiziana is a clinical-stage biotech with no product revenue, running several early-stage trials of its antibody foralumab.

What's Happening Right Now

• Fri 16th Oct '26 · Trial milestone: On Oct 16, 2026, Tiziana finished dosing the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's disease, with topline data expected in Q1 2027.
• Wed 30th Sep '26 · Regulatory: On Sep 30, 2026, Tiziana asked the FDA for orphan drug designation for intranasal foralumab in multiple system atrophy, an early regulatory step rather than a clinical decision.
• Mon 28th Sep '26 · Trial start: On Sep 28, 2026, Tiziana dosed the first three patients in a Phase 2a ALS trial of intranasal foralumab, an early execution milestone with no efficacy data yet.
• Mon 21st Sep '26 · Trial milestone: On Sep 21, 2026, the last patient completed final visits in the Phase 2a INFORM-MS trial of intranasal foralumab in secondary progressive MS, setting up a topline data readout.
• Fri 31st Jul '26 · Trial data: On Jul 31, 2026, Tiziana reported PET imaging showing reduced brain inflammation in a third multiple system atrophy patient treated with intranasal foralumab.
• Mon 19th Jan '26 · Warrants: Issued warrants over 8.80M shares.
• Fri 16th Jan '26 · ATM sale: Sold 1.21M shares through its at-the-market program, as stated for Jul 1, 2025 to Jan 16, 2026.
• Wed 31st Dec '25 · ATM sale: Sold $10.06M net through its at-the-market program, as stated for Jan 1, 2025 to Dec 31, 2025.